| Drug ID: | Drug85 |
|---|---|
| Drug Name: | Butyrate |
| CID: | 5222465 |
| DrugBank ID: | NULL |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NULL |
| Other Approved: | NULL |
| Identifier: | NCT05218850 |
| Molecular Formula: | C4H7NaO2 |
| Molecular Weight: | 110.09 g/mol |
| Isomeric SMILES: | CCCC(=O)[O-].[Na+] |
| Synonyms: | SODIUM BUTYRATE; 156-54-7; Butyric acid sodium salt; Butanoic acid, sodium salt; Butyrate sodium; Butyric acid, sodium salt; CCRIS 7068; Sodium butyrate (USP); Sodium butyrate [USP]; HSDB 5655 |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 0 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt706 | 5222465 | Sodium Butyrate | 3689 | ITGB2 | Homo sapiens (human) | None | |
| dt707 | 5222465 | Sodium Butyrate | 2026 | ENO2 | Homo sapiens (human) | None | |
| dt708 | 5222465 | Sodium Butyrate | 2670 | GFAP | Homo sapiens (human) | None | |
| dt709 | 5222465 | Sodium Butyrate | 2641 | GCG | Homo sapiens (human) | None | |
| dt710 | 5222465 | Sodium Butyrate | 7052 | TGM2 | Homo sapiens (human) | None | |
| dt711 | 5222465 | Sodium Butyrate | 3065 | HDAC1 | Homo sapiens (human) | Inhibitor | |
| dt712 | 5222465 | Sodium Butyrate | 64061 | TSPYL2 | Homo sapiens (human) | None | |
| dt713 | 5222465 | Sodium Butyrate | 4363 | ABCC1 | Homo sapiens (human) | None | |
| dt714 | 5222465 | Sodium Butyrate | 6696 | SPP1 | Homo sapiens (human) | None | |
| dt715 | 5222465 | Sodium Butyrate | 94025 | MUC16 | Homo sapiens (human) | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT06351124 | Feasibility of Beta-hydroxybutyrate Supplementation to Reduce Inflammation in Patients with Inflammatory Bowel Disease | PHASE1|PHASE2 | Recruiting | University of Texas at Austin | Crohn's Disease;Inflammatory Bowel Diseases | Biological: Feasibility of beta-hydroxybutyrate s… | Details |
| NCT04879914 | Inflammation and Intestinal Microbiota Modulation in Inflammatory Bowel Diseases | Not Available | Not recruiting | University of Padova | Inflammatory Bowel Diseases;Irritable Bowel Syndr… | Dietary Supplement: Butyrate;Dietary Supplement: … | Details |
| NCT05456763 | Butyrate in Pediatric Inflammatory Bowel Disease | None | COMPLETED | Centre of Postgraduate Medical Education | Inflammatory Bowel Diseases | DIETARY_SUPPLEMENT: sodium butyrate|OTHER: placebo | Details |
| NCT05218850 | The Use of Butyrate Therapy in Pediatric Ulcerative Colitis | PHASE1 | RECRUITING | Children's Hospital Los Angeles | Ulcerative Colitis | DRUG: Butyrate | Details |
| NCT04259060 | Hydroxocobalamin Approach for Reducing of Calprotectin With Butyrate for Ulcerative Colitis Remission | PHASE2 | WITHDRAWN | Joshua Korzenik | Ulcerative Colitis | DRUG: Hydroxocobalamin with Butyrate|DRUG: Placeb… | Details |
| NCT01282905 | Hydrogen Sulfide Detoxification and Butyrate Metabolism in Ulcerative Colitis | None | COMPLETED | KU Leuven | Ulcerative Colitis | None | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Sodium Butyrate Inhibits Oxidative Stress and NF-κB/NLRP3 Activation in Dextran…
PMID: 36867295
Year: 2023
Relationship Type:
Mechanism
Score: 10.0
BACKGROUND: Sodium butyrate (NaB) is a short-chain fatty acid produced by intestinal microbial fermentation of dietary fiber, and has been shown to b…
Sodium Butyrate-Loaded Microspheres With Enhanced Bioavailability for Targeted …
PMID: 39629540
Year: 2025
Relationship Type:
Treatment
Score: 8.5
Intestinal barrier dysfunction is related to diseases such as inflammatory bowel disease (IBD) and severe acute pancreatitis (SAP). Butyrate and its …
Clinical Efficacy of Sodium Butyrate in Managing Pediatric Inflammatory Bowel D…
PMID: 40566555
Year: 2025
Relationship Type:
Treatment
Score: 7.5
BACKGROUND: Few studies have evaluated the efficacy of butyric acid in treating children with inflammatory bowel disease (IBD). In children and adole…
Effects of Microencapsulated Sodium Butyrate, Probiotics and Short Chain Fructo…
PMID: 36362815
Year: 2022
Relationship Type:
Treatment
Score: 7.5
Irritable bowel syndrome (IBS) is a functional gastrointestinal disease in the pathogenesis of which gut dysbiosis may play an important role. Thus, …
Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed …
PMID: 36014789
Year: 2022
Relationship Type:
Treatment
Score: 7.5
BACKGROUND: Butyric acid's effectiveness has not yet been assessed in the pediatric inflammatory bowel disease (IBD) population. This study aimed to …
The deficiency of chymase mast cell protease 4 exacerbates dextran sulfate sodi…
PMID: 40697820
Year: 2025
Relationship Type:
Mechanism
Score: 6.5
INTRODUCTION: Ulcerative colitis (UC) is a chronic gastrointestinal disease characterized by symptoms of abdominal pain and diarrhea. Chymase is a se…
Activation of PPARγ regulates M1/M2 macrophage polarization and attenuates dext…
PMID: 39737788
Year: 2025
Relationship Type:
Treatment
Score: 6.5
This study aimed to investigate whether activation of PPARgamma regulates M1/M2 macrophage polarization to attenuate dextran sulfate sodium salt (DSS…
Mannose enhances intestinal immune barrier function and dextran sulfate sodium …
PMID: 38529272
Year: 2024
Relationship Type:
Mechanism
Score: 6.5
BACKGROUND: Inflammatory bowel disease (IBD) greatly affects human quality of life. Mannose has been reported to be used to treat IBD, but the mechan…
Oat Peptides Alleviate Dextran Sulfate Sodium Salt-Induced Colitis by Maintaini…
PMID: 38140314
Year: 2023
Relationship Type:
Mechanism
Score: 6.5
The prevalence of inflammatory bowel disease (IBD) is progressively rising each year, emphasizing the significance of implementing rational dietary i…
α-Lipoic acid alleviates dextran sulfate sodium salt-induced ulcerative colitis…
PMID: 37850313
Year: 2024
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Inflammatory bowel disease (IBD) is a chronically relapsing inflammatory disease with severe diarrhea, fatigue and weight loss. alpha-Lip…
The effect of olsalazine of chinese generic drugs on ulcerative colitis induced…
PMID: 37610966
Year: 2023
Relationship Type:
Treatment
Score: 6.5
PURPOSE: To explore effect and mechanism of olsalazine of Chinese generic drugs on ulcerative colitis induced by dextran sulfate sodium salt (DSS) in…
Myricetin and M10, a myricetin-3-O-β-d-lactose sodium salt, modify composition …
PMID: 33811973
Year: 2021
Relationship Type:
Treatment
Score: 6.5
Our previous studies found that M10, a myricetin-3-O-beta-d-lactose sodium salt, possessed higher effects of ameliorating ulcerative colitis (UC) tha…
Development of M10, myricetin-3-O-β-d-lactose sodium salt, a derivative of myri…
PMID: 31022552
Year: 2019
Relationship Type:
Treatment
Score: 6.5
Myricetin is a natural dietary flavonoid compound with multiple activities, such as anti-oxidant, anti-inflammatory, anti-carcinogenic and anti-proli…
Sodium butyrate alleviates colitis by inhibiting mitochondrial ROS mediated mac…
PMID: 40044062
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease (IBD) is a chronic inflammatory bowel disease with unclear causes and limited treatment options. Sodium butyrate (NaB), a …
Sodium butyrate alleviates DSS-induced inflammatory bowel disease by inhibiting…
PMID: 40028886
Year: 2025
Relationship Type:
Mechanism
Score: 6.5
BACKGROUND: Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), can seriously impact patients' quality o…
Sodium Butyrate Protects Against Intestinal Oxidative Damage and Neuroinflammat…
PMID: 37665564
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel diseases (IBD) cause increased inflammatory signalling and oxidative damage. IBDs are correlated with an increased incidence of br…
The novel sustained 3-hydroxybutyrate donor poly-D-3-hydroxybutyric acid preven…
PMID: 36562544
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease (IBD) is a chronic persistent intestinal disorder, with ulcerative colitis and Crohn's disease being the most common. Howe…
Sodium butyrate treatment and fecal microbiota transplantation provide relief f…
PMID: 36389141
Year: 2022
Relationship Type:
Treatment
Score: 6.5
The ability to regulate the gut environment has resulted in remarkable great breakthroughs in the treatment of several diseases. Several studies have…
The effectiveness of microencapsulated sodium butyrate at reducing symptoms in …
PMID: 35371361
Year: 2022
Relationship Type:
Treatment
Score: 6.5
AIM: The aim of the study was to assess the effectiveness of a patented preparation of sodium butyrate in the triglyceride matrix at reducing clinica…
Synergistic enhancement of rat intestinal alkaline phosphatase activity by taur…
PMID: 35322465
Year: 2022
Relationship Type:
Association
Score: 6.5
The effect of sodium butyrate (SB) and taurine on rat intestinal alkaline phosphatase (RIA) and the effect of the interaction of taurine and/or SB wi…